Nicholas A Vitanza, MD

Nicholas A Vitanza, MD

Cancer and Blood Disorders Center, Brain Tumor Program, Immunotherapy Program

On staff since August 2016

Children's Title: Attending Physician, Cancer and Blood Disorders Center

Academic Title: Associate Professor, Hematology/Oncology

Research Title: CNS CAR T Cell Lead, DIPG Research Lead

Research Center: Ben Towne Center for Childhood Cancer Research

"My goal is to find safer and more effective therapies for children with central nervous system (CNS) tumors (meaning, tumors of the brain and spine). As a pediatric neuro-oncologist, the director of the Vitanza Lab at the Ben Towne Center for Childhood Cancer Research, and our CNS CAR T cell lead, I am fortunate to work at the intersection where laboratory science translates to new clinical trials. Our work has helped advance epigenetically targeted drugs and targeted immunotherapies - such as CAR T cells - to the clinic for patients with fatal tumors such as diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and atypical teratoid rhabdoid tumor (ATRT). Overseeing our multiple open CNS CAR T cell trials has allowed me to connect with in need families from all over the world and our pledge is to provide expert, compassionate care to each child we meet."

  • Dr. Nicholas Vitanza is a pediatric neuro-oncologist and translational scientist whose career is dedicated to the care of children with high-grade CNS tumors, particularly diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma H3K27M-altered (DMG), and atypical teratoid rhabdoid tumor (ATRT). During his pediatric oncology fellowship with Drs. Bill Carroll and Elizabeth Raetz at New York University, laboratory projects led to a COG clinical trial and an ASPHO award. He completed a second fellowship in pediatric neuro-oncology at Stanford University and a post-doc in Michelle Monje’s neuroscience/DIPG Lab, in which he performed high-throughput drug screens in patient-derived DIPG models and mechanistic analyses of epigenetic vulnerabilities in DIPG. This work led to publications in Cancer Cell and Science Translational Medicine, as well as a phase 1 clinical trial.

    In 2016, Dr. Vitanza joined the faculty at Seattle Children’s Hospital. His work and the work of the Vitanza Lab has focused on creating treatment-naïve biopsy-derived patient-derived DIPG/DMG models, discovering targetable molecular and immunologic vulnerabilities in these tumors, and translating these findings into innovative new clinical trials. Dr. Vitanza serves as Seattle Children’s DIPG Research Lead, overseeing a dedicated research program spanning laboratory work to patient care, and CNS CAR T Cell Lead, overseeing CAR T cell clinical trials for brain and spinal cord tumor patients. He has served as the Study Chair of multiple trials delivering repeated, locoregional chimeric antigen receptor (CAR) T cells, including BrainChild-01 (targeting HER2), BrainChild-02 (targeted EGFR), BrainChild-03 (targeting B7-H3), and BrainChild-04 (multi-antigen targeting of HER, EGFR, B7-H3, and IL-13ra2). BrainChild-03 and BrainChild-04 continue to actively enroll patients. His work has been shared at international conferences such as the International Society of Pediatric Neuro-Oncology and published in journals such as Neuro-Oncology, Nature Medicine, and Cancer Discovery. He was also an invited researcher to the Cancer Moonshot Brain Tumor Forum at the White House in 2023.

    His goal is to better understand vulnerabilities in DIPG, DMG, and ATRT; translate those scientific discoveries into improved outcomes for affected children; and ultimately cure the remaining incurable CNS tumors of childhood.


    • Related Pages

    • Vitanza Lab

      The Vitanza lab searches for new treatments that are both safe and curative for aggressive pediatric brain and spinal cord tumors, such as diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma H3 K27M-mutant (DMG), and atypical teratoid rhabdoid tumor (ATRT).

    • Diffuse Intrinsic Pontine Glioma Research Program

      Diffuse intrinsic pontine glioma (DIPG) and diffuse midline gliomas (DMG) are aggressive childhood cancers. The DIPG Research Program at Seattle Children’s focuses on development of new therapies for aggressive brain and central nervous system tumors through optimization of clinical care.

    • Ryan Sandy Utah 04.06.21

      Dr Vitanza is the absolute best of the best. He has been guiding us with our five year old daughter, who was diagnosed with DIPG brain cancer, since the summer of 2020. Not only is he extremely knowledgeable about his field of work, he is extremely compassionate and goes above and beyond to to provide support to families that have been dealt the most unimaginable diagnosis for their child. I feel that Dr. Vitanza has the children’s absolutely best interest at heart and his medical advice is a balance of beating the disease they have, while factoring in the best possible quality of life for their situation. I have never met a medical professional to his degree of patient dedication. He is also extremely responsive to any questions or concerns we have had and has an unrivaled response time to any questions we have directed to him. I am a hard person to gain my loyalty and trust and I can assure you that Dr. Vitanza has my complete trust for guidance for my daughter whom I care more about than anyone in this world. I would normally try and add some negative qualities to a review like this for a balanced critique but I honestly have nothing negative to say. Seattle Children’s is fortunate to have such dedicated Dr’s and staff.

    • Scott Issaquah, WA 04.11.19

      In November of 2017, my 12-year-old son was diagnosed with a brain tumor at Seattle Children's Hospital. Dr. Vitanza lead a team of doctors, nurses, surgeons, technicians and radiologists with the sole purpose of saving my son's life. Dr. Vitanza wears many hats. He is a pediatric oncologist, renowned brain cancer researcher and father. We felt the presence of all of these roles in his work from delivering diagnoses, crafting and communicating a plan and in the compassion he shows in leading you through the one of the most terrifying journeys a parent can walk, a brain cancer diagnosis in their child. Dr. Vitanza makes a clear effort to personally connect with his patients and support parents with their questions and concerns. The care he shows in elevating his professional standards as a doctor show in his reputation amongst cancer families. Dr. Vitanza was the physician that first told us our son had cancer and 6 difficult months later, he was the physician that told us our son's brain showed no evidence of disease. We are forever indebted to Dr. Vitanza's professional excellence and the humanity that consistently precedes it.

    • Wendy Newcastle 02.17.19

      A pediatric hematologist-oncologist is not a doctor I ever thought our family would have in our address book. With a child who has appointments in the Hemoc Clinic, we are now part of a club that nobody wants to join, and the dues required to belong to this club are more than anyone would ever want to pay. But now that we find ourselves a part of this club, we are beyond grateful that Dr. Vitanza is our doctor. Given our daughter’s complicated situation (tumor in spine involving Neuro and Ortho), we have several, but he is our main go-to physician. From the moment we met him we were very fond of him. In one of the most frightening situations one can be dealt in life, his soft spoken delivery, empathetic nature, medical knowledge, and brilliance is very appreciated. He explains things patiently and thoroughly. Dr. Vitanza is always quick to respond with any question that we have. He promptly addresses our concerns and/or puts us in the right hands to do so. With the frightening feelings and urgent nature of care needed that accompany a sick child, having the support of Dr. Vitanza on board is priceless. We (and most importantly our daughter) think he is amazing and adore him!

    • Mack Chicago, IL 01.19.19

      When our granddaughter was diagnosed with a DIPG (a tumor of the brain that doesn’t have any cures), Doctor Vitanza was willing to speak to our entire family on the phone to get recommendations on medical trials. Even though we have never met, me and my daughter will be forever grateful for his compassion and his guidance.

    • Kristie Seattle, WA 09.21.17

      In our ten months at SCH, we had countless interactions with surgeons, oncologists, nurses, lab technicians, therapists, receptionists, assistants, parking attendants, etc. Some have been better than others, but overall, we were very happy with our care. There is however one individual that truly stands out among them all. Nick Vitanza. I'll never forget the day we met Dr. Vitanza. We were learning the fate of our 11 year old daughter. We gathered in a room with what would become our team. The people that would become our family in so many ways. Today, I can honestly say I genuinely like and respect each and every person that was in that room that first day. I consider them our friends and confidants. They were delivering to us the hardest news one has to deliver to anyone. That our daughter had an extremely rare, highly aggressive, brain tumor in an impossible to get to location. We were given a wealth of information and none of it was good. Nick had just started at SCH days before. I could tell he was the new guy, not only because it was mentioned, but also because he was slightly hesitant in when to speak, wanting to be respectful to his own new team. But he did speak and one of the most clear things I remember from that blur of a meeting is him stopping me at the end, looking me straight in the eye and saying clearly and plainly, "We will take excellent care of your daughter." I held onto that promise and you know what, they did. And in particular, Nick Vitanza did. He truly went above and beyond. His bedside manner is unmatched. He is thoughtful, extremely sharp, caring, respectful and always makes you feel like you're his only patient, which I imagine has got to be a real challenge knowing what their caseload looks like. Dr. Vitanza works tirelessly on behalf of our children and SCH is very lucky to have him.

  • Award Name Award Description Awarded By Award Date
    Community Hero Award Seattle Sounders 2021
    Outstanding Research Award Stanford University, 7th Annual Stanford Pediatric Research Retreat 2016
    Outstanding Research Commendation International Society of Pediatric Neuro-Oncology Conference, Liverpool, UK 2016
    Young Investigator Award American Society of Pediatric Hematology/Oncology 2014
    Research Training Award for Fellows (RTAF) American Society of Hematology 2013
    Frances Pope Memorial Foundation Fellow New York University Langone Medical Center 2012
    Resident Researcher of the Year Award Stony Brook University 2011
    Resident Teacher of the Year Award Stony Brook University 2009
  • Book Chapters

    • Vitanza NA, Campen CJ, Fisher PG
      Epidemiology of Pediatric CNS Tumors
      Brain Tumors in Children, 2018
    • Vitanza NA, Fisher PG, Monje M.
      Diffuse Intrinsic Pontine Glioma
      Swaiman's Pediatric Neurology: Principles and Practice , 7th Editio(2023)

    Other Publications

    • Findlay IJ, De Iuliis GN, Duchatel RJ, Jackson ER, Vitanza NA, Cain JE, Waszak SM, Dun MD
      Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
      34759345 Oncogene, 2021 Nov 10
    • Ganapathi SS, Havard ME, Ferguson M, Cole BL, Millard NE, Vitanza NA
      Extramedullary Hematopoiesis in the Dura Mater During Treatment of a CNS Embryonal Tumor.
      33031159 Journal of pediatric hematology/oncology, 2021 Nov 1 : 43(8)e1217-e1219
    • Zhang M, Wong SW, Wright JN, Toescu S, Mohammadzadeh M, Han M, Lummus S, Wagner MW, Yecies D, Lai H, Eghbal A, Radmanesh A, Nemelka J, Harward S, Malinzak M, Laughlin S, Perreault S, Braun KRM, Vossough A, Poussaint T, Goetti R, Ertl-Wagner B, Ho CY, Oztekin O, Ramaswamy V, Mankad K, Vitanza NA, Cheshier SH, Said M, Aquilina K, Thompson E, Jaju A, Grant GA, Lober RM, Yeom KW
      Machine Assist for Pediatric Posterior Fossa Tumor Diagnosis: A Multinational Study.
      34392363 Neurosurgery, 2021 Oct 13 : 89(5)892-900
    • Field MT, Chapple A, Hoeppner C, Boiko JR, Tellinghuisen A, Joshi S, Vitanza NA
      Care Coordination in a SARS-CoV-2-infected Child With Newly Diagnosed Medulloblastoma and Fanconi Anemia.
      33235157 Journal of pediatric hematology/oncology, 2021 Oct 1 : 43(7)e972-e974
    • Karajannis MA, Mauguen A, Maloku E, Xu Q, Dunbar EM, Plotkin SR, Yaffee A, Wang S, Roland JT, Sen C, Placantonakis DG, Golfinos JG, Allen JC, Vitanza NA, Chiriboga LA, Schneider RJ, Deng J, Neubert TA, Goldberg JD, Zagzag D, Giancotti FG, Blakeley JO
      Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.
      34224367 Molecular cancer therapeutics, 2021 Sept. : 20(9)1584-1591 PMCID:PMC8419097
    • Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Künkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, Albert CM, Pinto N, Gust J, Finn LS, Ojemann JG, Wright J, Orentas RJ, Baldwin M, Gardner RA, Jensen MC, Park JR
      Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
      34253928 Nature medicine, 2021 Sept. : 27(9)1544-1552
    • Vitanza NA, Biery MC, Myers C, Ferguson E, Zheng Y, Girard EJ, Przystal JM, Park G, Noll A, Pakiam F, Winter CA, Morris SM, Sarthy J, Cole BL, Leary SES, Crane C, Lieberman NAP, Mueller S, Nazarian J, Gottardo R, Brusniak MY, Mhyre AJ, Olson JM
      Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
      33130903 Neuro-oncology, 2021 Mar 25 : 23(3)376-386 PMCID:PMC7992886
    • Vitanza NA, Khalatbari H, Ermoian R, Sarthy J, Lockwood CM, Cole BL, Leary SES
      Molecularly Targeted Treatments for NF1-Mutant Diffuse Intrinsic Pontine Glioma.
      32862234 The journal of applied laboratory medicine, 2021 Mar 1 : 6(2)550-553
    • Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S, Hwang E, Vitanza N, Okada H
      Considerations when treating high-grade pediatric glioma patients with immunotherapy.
      33225764 Expert review of neurotherapeutics, 2021 Feb. : 21(2)205-219 PMCID:PMC7880880
    • Tam LT, Yeom KW, Wright JN, Jaju A, Radmanesh A, Han M, Toescu S, Maleki M, Chen E, Campion A, Lai HA, Eghbal AA, Oztekin O, Mankad K, Hargrave D, Jacques TS, Goetti R, Lober RM, Cheshier SH, Napel S, Said M, Aquilina K, Ho CY, Monje M, Vitanza NA, Mattonen SA
      MRI-based radiomics for prognosis of pediatric diffuse intrinsic pontine glioma: an international study.
      33977272 Neuro-oncology advances, 2021 Jan. : 3(1)vdab042 PMCID:PMC8095337
    • Petralia F, Tignor N, Reva B, Koptyra M, Chowdhury S, Rykunov D, Krek A, Ma W, Zhu Y, Ji J, Calinawan A, Whiteaker JR, Colaprico A, Stathias V, Omelchenko T, Song X, Raman P, Guo Y, Brown MA, Ivey RG, Szpyt J, Guha Thakurta S, Gritsenko MA, Weitz KK, Lopez G, Kalayci S, Gümüş ZH, Yoo S, da Veiga Leprevost F, Chang HY, Krug K, Katsnelson L, Wang Y, Kennedy JJ, Voytovich UJ, Zhao L, Gaonkar KS, Ennis BM, Zhang B, Baubet V, Tauhid L, Lilly JV, Mason JL, Farrow B, Young N, Leary S, Moon J, Petyuk VA, Nazarian J, Adappa ND, Palmer JN, Lober RM, Rivero-Hinojosa S, Wang LB, Wang JM, Broberg M, Chu RK, Moore RJ, Monroe ME, Zhao R, Smith RD, Zhu J, Robles AI, Mesri M, Boja E, Hiltke T, Rodriguez H, Zhang B, Schadt EE, Mani DR, Ding L, Iavarone A, Wiznerowicz M, Schürer S, Chen XS, Heath AP, Rokita JL, Nesvizhskii AI, Fenyö D, Rodland KD, Liu T, Gygi SP, Paulovich AG, Resnick AC, Storm PB, Rood BR, Wang P, Children’s Brain Tumor Network., Clinical Proteomic Tumor Analysis Consortium.
      Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer.
      33242424 Cell, 2020 Dec 23 : 183(7)1962-1985.e31 PMCID:PMC8143193
    • Biery MC, Noll A, Myers C, Morris SM, Winter CA, Pakiam F, Cole BL, Browd SR, Olson JM, Vitanza NA
      A Protocol for the Generation of Treatment-naïve Biopsy-derived Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma Models.
      33768215 Journal of experimental neurology, 2020 Dec. : 1(4)158-167 PMCID:PMC7990285
    • Sarthy JF, Meers MP, Janssens DH, Henikoff JG, Feldman H, Paddison PJ, Lockwood CM, Vitanza NA, Olson JM, Ahmad K, Henikoff S
      Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones.
      32902381 eLife, 2020 Sep 9 : 9 PMCID:PMC7518889
    • Crotty EE, Leary SES, Geyer JR, Olson JM, Millard NE, Sato AA, Ermoian RP, Cole BL, Lockwood CM, Paulson VA, Browd SR, Ellenbogen RG, Hauptman JS, Lee A, Ojemann JG, Vitanza NA
      Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
      32556862 Journal of neuro-oncology, 2020 July : 148(3)607-617
    • Michaiel G, Strother D, Gottardo N, Bartels U, Coltin H, Hukin J, Wilson B, Zelcer S, Hansford JR, Hassall T, AbdelBaki MS, Cole KA, Hoffman L, Smiley NP, Smith A, Vinitsky A, Vitanza NA, Wright A, Yeo KK, Chow LML, Vanan MI, Dhall G, Bouffet E, Lafay-Cousin L
      Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature.
      32297094 Journal of neuro-oncology, 2020 May : 147(3)721-730
    • Williams JR, Young CC, Vitanza NA, McGrath M, Feroze AH, Browd SR, Hauptman JS
      Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
      31896081 Neurosurgical focus, 2020 Jan 1 : 48(1)E4
    • Ravanpay AC, Gust J, Johnson AJ, Rolczynski LS, Cecchini M, Chang CA, Hoglund VJ, Mukherjee R, Vitanza NA, Orentas RJ, Jensen MC
      EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma.
      31903167 Oncotarget, 2019 Dec 17 : 10(66)7080-7095 PMCID:PMC6925027
    • Lin GL, Wilson KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, Qin EY, Zhang X, Lennon J, Nagaraja S, Morris PJ, Quezada M, Gillespie SM, Duveau DY, Michalowski AM, Shinn P, Guha R, Ferrer M, Klumpp-Thomas C, Michael S, McKnight C, Minhas P, Itkin Z, Raabe EH, Chen L, Ghanem R, Geraghty AC, Ni L, Andreasson KI, Vitanza NA, Warren KE, Thomas CJ, Monje M
      Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.
      31748226 Science translational medicine, 2019 Nov 20 : 11(519) PMCID:PMC7132630
    • Ermoian RP, Vitanza NA
      No Further Therapy.
      31327426 International journal of radiation oncology, biology, physics, 2019 Aug 1 : 104(5)969-970
    • Vitanza NA, Monje M
      Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.
      31290035 Current treatment options in neurology, 2019 Jul 10 : 21(8)37
    • Steineck A, Krumm N, Sarthy JF, Pritchard CC, Chapman T, Stacey AW, Vitanza NA, Cole B
      Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma.
      32923855 JCO precision oncology, 2019 : 3 PMCID:PMC7446378
    • Lieberman NAP, DeGolier K, Kovar HM, Davis A, Hoglund V, Stevens J, Winter C, Deutsch G, Furlan SN, Vitanza NA, Leary SES, Crane CA
      Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
      30169876 Neuro-oncology, 2019 Jan 1 : 21(1)83-94 PMCID:PMC6303470
    • Bayart CB, Ishak GE, Finn LS, Lee A, Baran F, Sun A, Gupta D, Vitanza NA
      Pilocytic astrocytoma with leptomeningeal spread in a patient with incontinentia pigmenti presenting with unilateral nystagmus.
      29171168 Pediatric blood & cancer, 2018 March : 65(3)
    • Lieberman NAP, Vitanza NA, Crane CA
      Immunotherapy for brain tumors: understanding early successes and limitations.
      29322843 Expert review of neurotherapeutics, 2018 March : 18(3)251-259
    • Rogawski DS, Vitanza NA, Gauthier AC, Ramaswamy V, Koschmann C
      Integrating RNA sequencing into neuro-oncology practice.
      28746860 Translational research : the journal of laboratory and clinical medicine, 2017 Nov. : 18993-104 PMCID:PMC5659901
    • Marini BL, Benitez LL, Zureick AH, Salloum R, Gauthier AC, Brown J, Wu YM, Robinson DR, Kumar C, Lonigro R, Vats P, Cao X, Kasaian K, Anderson B, Mullan B, Chandler B, Linzey JR, Camelo-Piragua SI, Venneti S, McKeever PE, McFadden KA, Lieberman AP, Brown N, Shao L, Leonard MAS, Junck L, McKean E, Maher CO, Garton HJL, Muraszko KM, Hervey-Jumper S, Mulcahy-Levy JM, Green A, Hoffman LM, Dorris K, Vitanza NA, Wang J, Schwartz J, Lulla R, Smiley NP, Bornhorst M, Haas-Kogan DA, Robertson PL, Chinnaiyan AM, Mody R, Koschmann C
      Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.
      28860053 Translational research : the journal of laboratory and clinical medicine, 2017 Oct. : 18827.e1-27.e14 PMCID:PMC5584679
    • Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Liu F, Zhang L, Li M, Meng W, Ponnuswami A, Sun W, Ma J, Hulleman E, Swigut T, Wysocka J, Tang Y, Monje M
      Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
      28434841 Cancer cell, 2017 May 8 : 31(5)635-652.e6 PMCID:PMC5462626
    • Vitanza NA, Partap S
      Pediatric Ependymoma.
      26503805 Journal of child neurology, 2016 Oct. : 31(12)1354-66
    • Vitanza NA
      50 Years Ago in TheJournal ofPediatrics: Induction of Remission in Acute Leukemia of Childhood by Combination of Prednisone and Either 6-Mercaptopurine or Methotrexate.
      27234282 The Journal of pediatrics, 2016 June : 173100
    • Vitanza NA, Shaw TM, Gardner SL, Allen JC, Harter DH, Karajannis MA
      Noncarboplatin-induced Sensorineural Hearing Loss in a Patient With an Intracranial Nongerminomatous Germ Cell Tumor.
      23652864 Journal of pediatric hematology/oncology, 2016 May : 38(4)312-6
    • Vitanza NA, Cho YJ
      Advances in the biology and treatment of pediatric central nervous system tumors.
      26709691 Current opinion in pediatrics, 2016 Feb. : 28(1)34-9
    • Vitanza NA, Hogan LE, Zhang G, Parker RI
      The Progression of Bone Mineral Density Abnormalities After Chemotherapy for Childhood Acute Lymphoblastic Leukemia.
      25222061 Journal of pediatric hematology/oncology, 2015 July : 37(5)356-61
    • Vitanza NA
      50 Years Ago in The Journal of Pediatrics: A Long-Term Study of Cerebrospinal Leukemia.
      26117636 The Journal of pediatrics, 2015 July : 167(1)80
    • Vitanza NA, Zaky W, Blum R, Meyer JA, Wang J, Bhatla T, Morrison DJ, Raetz EA, Carroll WL
      Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.
      24976218 Pediatric blood & cancer, 2014 Oct. : 61(10)1779-85 PMCID:PMC4217284
    • Bhatla T, Jones CL, Meyer JA, Vitanza NA, Raetz EA, Carroll WL
      The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.
      24942023 Journal of pediatric hematology/oncology, 2014 Aug. : 36(6)413-8 PMCID:PMC4264573

  • Grant Title Grantor Amount Award Date
    We Love You Connie Foundation Research Grant 2022 - 2026
    Cookies for Kid's Cancer Translational Science Award 2021 - 2023
    Defeat DIPG/ChadTough Young Investigator Award 2019 - 2020
    American Society of Hematology Research Training Award Jul 1, 2013 - Jun 30, 2014
    Brotman Baty Institute for Precision Medicine Catalytic Collaboration Award
    Matthew Larson Grant 2022


Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

American University of the Caribbean, Pembroke Pines, FL
New York University, New York, New York


State University of New York at Stony Brook, Stony Brook, NY


Lucile Salter Packard Children's Hospital-Stanford, Palo Alto, CA
New York University Langone Medical Center, New York, NY
NYU Langone Hospital, New York, NY
Stanford University School of Medicine, Stanford, CA

Clinical Interests

Brain and spinal cord tumors of childhood; diffuse intrinsic pontine glioma (DIPG); diffuse midline glioma (DMG); CAR T cell immunotherapy; early phase clinical trials

Research Description

My laboratory research focuses on developing new, targeted drugs and CAR T cell therapies against pediatric brain and spinal cord tumors, particularly diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and atypical teratoid rhabdoid tumor (ATRT).

Research Focus Area

Cancer biology, Early phase clinical trials for pediatric brain tumors